Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2021

05.03.2021 | review

Cognitive impairment in cancer patients and survivors—clinical presentation, pathophysiology, diagnosis and management

verfasst von: MD Markus Hutterer, Stefan Oberndorfer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Cognitive impairment by neurotoxic substances, administered alone or in a multidrug regimen, affects a large number of patients treated for noncentral nervous system cancer during and after chemotherapy with variable onset, severity and duration, but sustainably affecting the patients’ individual health-related quality of life. Depending on the mechanism of action, the ability to cross the blood–brain barrier into the central nervous system and the cumulative total dose of the cytotoxic drugs results in functional and structural brain changes. This neurotoxicity leads to negative effects on neural precursor cells (neurogenesis), microglia (neuroinflammation), neurons (cortical dysfunction with altered brain networks), and astro-/oligodendroglia (white matter tract demyelination) and therefore on patients’ cognitive performance. Memory and executive functions, attention/concentration, and processing speed are the cognitive domains commonly impaired by chemotherapy. Importantly, numerous simultaneously occurring risk factors may also have distinct restrictions on cognitive function. For this reason, the term cancer-related cognitive impairment (CRCI), implicating neurotoxicity in cancer patients with simultaneous consideration of other causes on cognitive performance, should be used. The aim of this review is to provide an update of the most recent clinical and pathophysiological findings, self-reported and neuropsychological testing methods, and the current management strategies of CRCI.
Literatur
1.
Zurück zum Zitat Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019;30(12):1925–40. PubMed Lange M, Joly F, Vardy J, Ahles T, Dubois M, Tron L, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019;30(12):1925–40. PubMed
2.
Zurück zum Zitat Huehnchen P, van Kampen A, Boehmerle W, Endres M. Cognitive impairment after cytotoxic chemotherapy. Neurooncol Pract. 2020;7(1):11–21. PubMed Huehnchen P, van Kampen A, Boehmerle W, Endres M. Cognitive impairment after cytotoxic chemotherapy. Neurooncol Pract. 2020;7(1):11–21. PubMed
3.
Zurück zum Zitat Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA A Cancer J Clin. 2015;65(2):123–38. Wefel JS, Kesler SR, Noll KR, Schagen SB. Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA A Cancer J Clin. 2015;65(2):123–38.
4.
Zurück zum Zitat Hermelink K. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2011;117(5):1103. author reply –4. PubMed Hermelink K. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2011;117(5):1103. author reply –4. PubMed
5.
Zurück zum Zitat Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 2007;109(9):1905–13. PubMed Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 2007;109(9):1905–13. PubMed
6.
Zurück zum Zitat Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, et al. Impact of cancer and its treatments on cognitive function: advances in research from the paris international cognition and cancer task force symposium and update since 2012. J Pain Symptom Manage. 2015;50(6):830–41. PubMed Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, et al. Impact of cancer and its treatments on cognitive function: advances in research from the paris international cognition and cancer task force symposium and update since 2012. J Pain Symptom Manage. 2015;50(6):830–41. PubMed
7.
Zurück zum Zitat Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30(30):3675–86. PubMedPubMedCentral Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30(30):3675–86. PubMedPubMedCentral
8.
Zurück zum Zitat Deprez S, Kesler SR, Saykin AJ, Silverman DHS, de Ruiter MB, McDonald BC. International cognition and cancer task force recommendations for neuroimaging methods in the study of cognitive impairment in non-CNS cancer patients. J Natl Cancer Inst. 2018;110(3):223–31. PubMedPubMedCentral Deprez S, Kesler SR, Saykin AJ, Silverman DHS, de Ruiter MB, McDonald BC. International cognition and cancer task force recommendations for neuroimaging methods in the study of cognitive impairment in non-CNS cancer patients. J Natl Cancer Inst. 2018;110(3):223–31. PubMedPubMedCentral
9.
Zurück zum Zitat Wefel JS, Vardy J, Ahles T, Schagen SB. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–8. PubMed Wefel JS, Vardy J, Ahles T, Schagen SB. International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–8. PubMed
10.
Zurück zum Zitat Trachtenberg E, Mashiach T, Ben Hayun R, Tadmor T, Fisher T, Aharon-Peretz J, et al. Cognitive impairment in hodgkin lymphoma survivors. Br J Haematol. 2018;182(5):670–8. PubMed Trachtenberg E, Mashiach T, Ben Hayun R, Tadmor T, Fisher T, Aharon-Peretz J, et al. Cognitive impairment in hodgkin lymphoma survivors. Br J Haematol. 2018;182(5):670–8. PubMed
11.
Zurück zum Zitat Lange M, Licaj I, Clarisse B, Humbert X, Grellard JM, Tron L, et al. Cognitive complaints in cancer survivors and expectations for support: results from a web-based survey. Cancer Med. 2019;8(5):2654–63. PubMedPubMedCentral Lange M, Licaj I, Clarisse B, Humbert X, Grellard JM, Tron L, et al. Cognitive complaints in cancer survivors and expectations for support: results from a web-based survey. Cancer Med. 2019;8(5):2654–63. PubMedPubMedCentral
12.
Zurück zum Zitat Biglia N, Bounous VE, Malabaila A, Palmisano D, Torta DM, D’Alonzo M, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care (Engl). 2012;21(4):485–92. Biglia N, Bounous VE, Malabaila A, Palmisano D, Torta DM, D’Alonzo M, et al. Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care (Engl). 2012;21(4):485–92.
13.
Zurück zum Zitat Ganz PA, Kwan L, Castellon SA, Oppenheim A, Bower JE, Silverman DH, et al. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst. 2013;105(11):791–801. PubMedPubMedCentral Ganz PA, Kwan L, Castellon SA, Oppenheim A, Bower JE, Silverman DH, et al. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance. J Natl Cancer Inst. 2013;105(11):791–801. PubMedPubMedCentral
14.
Zurück zum Zitat Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30(29):3578–87. PubMedPubMedCentral Jim HS, Phillips KM, Chait S, Faul LA, Popa MA, Lee YH, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30(29):3578–87. PubMedPubMedCentral
15.
Zurück zum Zitat Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004;22(11):2233–9. PubMed Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol. 2004;22(11):2233–9. PubMed
16.
Zurück zum Zitat Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer. 2008;113(9):2431–9. PubMed Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer. 2008;113(9):2431–9. PubMed
17.
Zurück zum Zitat Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20(2):485–93. PubMed Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20(2):485–93. PubMed
18.
Zurück zum Zitat Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer. 2011;19(10):1647–56. PubMed Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA. A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer. 2011;19(10):1647–56. PubMed
19.
Zurück zum Zitat Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292–9. PubMed Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292–9. PubMed
20.
Zurück zum Zitat Lindner OC, Phillips B, McCabe MG, Mayes A, Wearden A, Varese F, et al. A meta-analysis of cognitive impairment following adult cancer chemotherapy. Neuropsychology. 2014;28(5):726–40. PubMedPubMedCentral Lindner OC, Phillips B, McCabe MG, Mayes A, Wearden A, Varese F, et al. A meta-analysis of cognitive impairment following adult cancer chemotherapy. Neuropsychology. 2014;28(5):726–40. PubMedPubMedCentral
21.
Zurück zum Zitat Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T. A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev. 2013;39(3):297–304. PubMed Hodgson KD, Hutchinson AD, Wilson CJ, Nettelbeck T. A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treat Rev. 2013;39(3):297–304. PubMed
22.
Zurück zum Zitat Cruzado JA, Lopez-Santiago S, Martinez-Marin V, Jose-Moreno G, Custodio AB, Feliu J. Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. Support Care Cancer. 2014;22(7):1815–23. PubMed Cruzado JA, Lopez-Santiago S, Martinez-Marin V, Jose-Moreno G, Custodio AB, Feliu J. Longitudinal study of cognitive dysfunctions induced by adjuvant chemotherapy in colon cancer patients. Support Care Cancer. 2014;22(7):1815–23. PubMed
23.
Zurück zum Zitat Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33(34):4085–92. PubMedPubMedCentral Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33(34):4085–92. PubMedPubMedCentral
24.
Zurück zum Zitat Piai V, Prins JB, Verdonck-de Leeuw IM, Leemans CR, Terhaard CHJ, Langendijk JA, et al. Assessment of neurocognitive impairment and speech functioning before head and neck cancer treatment. JAMA Otolaryngol Head Neck Surg. 2019;145(3):251–7. PubMedPubMedCentral Piai V, Prins JB, Verdonck-de Leeuw IM, Leemans CR, Terhaard CHJ, Langendijk JA, et al. Assessment of neurocognitive impairment and speech functioning before head and neck cancer treatment. JAMA Otolaryngol Head Neck Surg. 2019;145(3):251–7. PubMedPubMedCentral
25.
Zurück zum Zitat Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012;38(7):926–34. PubMed Hutchinson AD, Hosking JR, Kichenadasse G, Mattiske JK, Wilson C. Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev. 2012;38(7):926–34. PubMed
27.
Zurück zum Zitat Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 1988;12(2):123–37. PubMed Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 1988;12(2):123–37. PubMed
28.
Zurück zum Zitat Hart BL. Behavioral adaptations to pathogens and parasites: five strategies. Neurosci Biobehav Rev. 1990;14(3):273–94. PubMed Hart BL. Behavioral adaptations to pathogens and parasites: five strategies. Neurosci Biobehav Rev. 1990;14(3):273–94. PubMed
30.
Zurück zum Zitat Collins B, MacKenzie J, Tasca GA, Scherling C, Smith A. Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. Psychooncology. 2013;22(7):1517–27. PubMed Collins B, MacKenzie J, Tasca GA, Scherling C, Smith A. Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. Psychooncology. 2013;22(7):1517–27. PubMed
31.
Zurück zum Zitat Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, et al. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Ann Oncol. 2015;26(7):1446–51. PubMedPubMedCentral Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, et al. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Ann Oncol. 2015;26(7):1446–51. PubMedPubMedCentral
32.
Zurück zum Zitat Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116(14):3348–56. PubMed Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116(14):3348–56. PubMed
33.
Zurück zum Zitat Wefel JS, Vidrine DJ, Marani SK, Swartz RJ, Veramonti TL, Meyers CA, et al. A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology. 2014;23(6):626–33. PubMed Wefel JS, Vidrine DJ, Marani SK, Swartz RJ, Veramonti TL, Meyers CA, et al. A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology. 2014;23(6):626–33. PubMed
34.
Zurück zum Zitat Gibson EM, Monje M. Emerging mechanistic underpinnings and therapeutic targets for chemotherapy-related cognitive impairment. Curr Opin Oncol. 2019;31(6):531–9. PubMedPubMedCentral Gibson EM, Monje M. Emerging mechanistic underpinnings and therapeutic targets for chemotherapy-related cognitive impairment. Curr Opin Oncol. 2019;31(6):531–9. PubMedPubMedCentral
35.
Zurück zum Zitat Gibson EM, Nagaraja S, Ocampo A, Tam LT, Wood LS, Pallegar PN, et al. Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment. Cell. 2019;176(1–2):43–55.e13. PubMed Gibson EM, Nagaraja S, Ocampo A, Tam LT, Wood LS, Pallegar PN, et al. Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment. Cell. 2019;176(1–2):43–55.e13. PubMed
36.
Zurück zum Zitat Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006;5(7):22. PubMedPubMedCentral Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol. 2006;5(7):22. PubMedPubMedCentral
37.
Zurück zum Zitat Dietrich J, Prust M, Kaiser J. Chemotherapy, cognitive impairment and hippocampal toxicity. Neuroscience. 2015;309:224–32. PubMed Dietrich J, Prust M, Kaiser J. Chemotherapy, cognitive impairment and hippocampal toxicity. Neuroscience. 2015;309:224–32. PubMed
38.
Zurück zum Zitat Geraghty AC, Gibson EM, Ghanem RA, Greene JJ, Ocampo A, Goldstein AK, et al. Loss of adaptive myelination contributes to methotrexate chemotherapy-related cognitive impairment. Neuron. 2019;103(2):250–65.e8. PubMedPubMedCentral Geraghty AC, Gibson EM, Ghanem RA, Greene JJ, Ocampo A, Goldstein AK, et al. Loss of adaptive myelination contributes to methotrexate chemotherapy-related cognitive impairment. Neuron. 2019;103(2):250–65.e8. PubMedPubMedCentral
39.
Zurück zum Zitat Monje ML, Mizumatsu S, Fike JR, Palmer TD. Irradiation induces neural precursor-cell dysfunction. Nat Med. 2002;8(9):955–62. PubMed Monje ML, Mizumatsu S, Fike JR, Palmer TD. Irradiation induces neural precursor-cell dysfunction. Nat Med. 2002;8(9):955–62. PubMed
40.
Zurück zum Zitat Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003;302(5651):1760–5. PubMed Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003;302(5651):1760–5. PubMed
41.
Zurück zum Zitat Dubois M, Lapinte N, Villier V, Lecointre C, Roy V, Tonon MC, et al. Chemotherapy-induced long-term alteration of executive functions and hippocampal cell proliferation: role of glucose as adjuvant. Neuropharmacology. 2014;79:234–48. PubMed Dubois M, Lapinte N, Villier V, Lecointre C, Roy V, Tonon MC, et al. Chemotherapy-induced long-term alteration of executive functions and hippocampal cell proliferation: role of glucose as adjuvant. Neuropharmacology. 2014;79:234–48. PubMed
42.
Zurück zum Zitat Christie LA, Acharya MM, Parihar VK, Nguyen A, Martirosian V, Limoli CL. Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin Cancer Res. 2012;18(7):1954–65. PubMed Christie LA, Acharya MM, Parihar VK, Nguyen A, Martirosian V, Limoli CL. Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin Cancer Res. 2012;18(7):1954–65. PubMed
43.
Zurück zum Zitat Mounier NM, Abdel-Maged AE, Wahdan SA, Gad AM, Azab SS. Chemotherapy-induced cognitive impairment (CICI): an overview of etiology and pathogenesis. Life Sci. 2020;258:118071. PubMed Mounier NM, Abdel-Maged AE, Wahdan SA, Gad AM, Azab SS. Chemotherapy-induced cognitive impairment (CICI): an overview of etiology and pathogenesis. Life Sci. 2020;258:118071. PubMed
44.
Zurück zum Zitat Lomeli N, Di K, Czerniawski J, Guzowski JF, Bota DA. Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats. Free Radic Biol Med. 2017;102:274–86. PubMed Lomeli N, Di K, Czerniawski J, Guzowski JF, Bota DA. Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats. Free Radic Biol Med. 2017;102:274–86. PubMed
45.
Zurück zum Zitat Seigers R, Timmermans J, van der Horn HJ, de Vries EF, Dierckx RA, Visser L, et al. Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav Brain Res. 2010;207(2):265–72. PubMed Seigers R, Timmermans J, van der Horn HJ, de Vries EF, Dierckx RA, Visser L, et al. Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav Brain Res. 2010;207(2):265–72. PubMed
46.
Zurück zum Zitat de Vos FY, Willemse PH, de Vries EG, Gietema JA. Endothelial cell effects of cytotoxics: balance between desired and unwanted effects. Cancer Treat Rev. 2004;30(6):495–513. PubMed de Vos FY, Willemse PH, de Vries EG, Gietema JA. Endothelial cell effects of cytotoxics: balance between desired and unwanted effects. Cancer Treat Rev. 2004;30(6):495–513. PubMed
47.
Zurück zum Zitat Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192–201. PubMedPubMedCentral Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192–201. PubMedPubMedCentral
48.
Zurück zum Zitat McEwen BS, Gould E, Orchinik M, Weiland NG, Woolley CS. Oestrogens and the structural and functional plasticity of neurons: implications for memory, ageing and neurodegenerative processes. Ciba Found Symp. 1995;191:52–66. discussion –73. PubMed McEwen BS, Gould E, Orchinik M, Weiland NG, Woolley CS. Oestrogens and the structural and functional plasticity of neurons: implications for memory, ageing and neurodegenerative processes. Ciba Found Symp. 1995;191:52–66. discussion –73. PubMed
49.
Zurück zum Zitat Le Rhun E, Delbeuck X, Lefeuvre-Plesse C, Kramar A, Skrobala E, Pasquier F, et al. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy. Breast Cancer Res Treat. 2015;152(3):569–80. PubMed Le Rhun E, Delbeuck X, Lefeuvre-Plesse C, Kramar A, Skrobala E, Pasquier F, et al. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy. Breast Cancer Res Treat. 2015;152(3):569–80. PubMed
50.
Zurück zum Zitat Wu LM, Amidi A. Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients. Curr Opin Support Palliat Care. 2017;11(1):38–45. PubMedPubMedCentral Wu LM, Amidi A. Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients. Curr Opin Support Palliat Care. 2017;11(1):38–45. PubMedPubMedCentral
51.
Zurück zum Zitat McGinty HL, Phillips KM, Jim HS, Cessna JM, Asvat Y, Cases MG, et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22(8):2271–80. PubMedPubMedCentral McGinty HL, Phillips KM, Jim HS, Cessna JM, Asvat Y, Cases MG, et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22(8):2271–80. PubMedPubMedCentral
52.
Zurück zum Zitat Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8(11):887–99. PubMed Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8(11):887–99. PubMed
54.
Zurück zum Zitat Seigers R, Pourtau L, Schagen SB, van Dam FS, Koolhaas JM, Konsman JP, et al. Inhibition of hippocampal cell proliferation by methotrexate in rats is not potentiated by the presence of a tumor. Brain Res Bull. 2010;81(4–5):472–6. PubMed Seigers R, Pourtau L, Schagen SB, van Dam FS, Koolhaas JM, Konsman JP, et al. Inhibition of hippocampal cell proliferation by methotrexate in rats is not potentiated by the presence of a tumor. Brain Res Bull. 2010;81(4–5):472–6. PubMed
55.
Zurück zum Zitat Yang M, Kim J, Kim JS, Kim SH, Kim JC, Kang MJ, et al. Hippocampal dysfunctions in tumor-bearing mice. Brain Behav Immun. 2014;36:147–55. PubMed Yang M, Kim J, Kim JS, Kim SH, Kim JC, Kang MJ, et al. Hippocampal dysfunctions in tumor-bearing mice. Brain Behav Immun. 2014;36:147–55. PubMed
56.
Zurück zum Zitat Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology. 2008;17(2):122–30. PubMed Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology. 2008;17(2):122–30. PubMed
57.
Zurück zum Zitat Demby TC, Rodriguez O, McCarthy CW, Lee YC, Albanese C, Mandelblatt J, et al. A mouse model of chemotherapy-related cognitive impairments integrating the risk factors of aging and APOE4 genotype. Behav Brain Res. 2020;384:112534. PubMedPubMedCentral Demby TC, Rodriguez O, McCarthy CW, Lee YC, Albanese C, Mandelblatt J, et al. A mouse model of chemotherapy-related cognitive impairments integrating the risk factors of aging and APOE4 genotype. Behav Brain Res. 2020;384:112534. PubMedPubMedCentral
58.
Zurück zum Zitat Ahles TA, Li Y, McDonald BC, Schwartz GN, Kaufman PA, Tsongalis GJ, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking. Psychooncology. 2014;23(12):1382–90. PubMedPubMedCentral Ahles TA, Li Y, McDonald BC, Schwartz GN, Kaufman PA, Tsongalis GJ, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking. Psychooncology. 2014;23(12):1382–90. PubMedPubMedCentral
59.
Zurück zum Zitat Cheng H, Li W, Gan C, Zhang B, Jia Q, Wang K. The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients. Am J Transl Res. 2016;8(11):5087–97. PubMedPubMedCentral Cheng H, Li W, Gan C, Zhang B, Jia Q, Wang K. The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients. Am J Transl Res. 2016;8(11):5087–97. PubMedPubMedCentral
60.
Zurück zum Zitat Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, et al. Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro Oncol. 2016;18(2):244–51. PubMed Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, et al. Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro Oncol. 2016;18(2):244–51. PubMed
61.
Zurück zum Zitat Tan CJ, Lim SWT, Toh YL, Ng T, Yeo A, Shwe M, et al. Replication and meta-analysis of the association between BDNF val66met polymorphism and cognitive impairment in patients receiving chemotherapy. Mol Neurobiol. 2019;56(7):4741–50. PubMed Tan CJ, Lim SWT, Toh YL, Ng T, Yeo A, Shwe M, et al. Replication and meta-analysis of the association between BDNF val66met polymorphism and cognitive impairment in patients receiving chemotherapy. Mol Neurobiol. 2019;56(7):4741–50. PubMed
62.
Zurück zum Zitat Merriman JD, Aouizerat BE, Cataldo JK, Dunn L, Cooper BA, West C, et al. Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast cancer. Cytokine. 2014;65(2):192–201. PubMed Merriman JD, Aouizerat BE, Cataldo JK, Dunn L, Cooper BA, West C, et al. Association between an interleukin 1 receptor, type I promoter polymorphism and self-reported attentional function in women with breast cancer. Cytokine. 2014;65(2):192–201. PubMed
63.
Zurück zum Zitat Sun H, Zhang G, Ai B, Zhang H, Kong X, Lee WT, et al. A systematic review: comparative analysis of the effects of propofol and sevoflurane on postoperative cognitive function in elderly patients with lung cancer. BMC. Cancer. 2019;19(1):1248. PubMedPubMedCentral Sun H, Zhang G, Ai B, Zhang H, Kong X, Lee WT, et al. A systematic review: comparative analysis of the effects of propofol and sevoflurane on postoperative cognitive function in elderly patients with lung cancer. BMC. Cancer. 2019;19(1):1248. PubMedPubMedCentral
64.
Zurück zum Zitat Voigt V, Neufeld F, Kaste J, Buhner M, Sckopke P, Wuerstlein R, et al. Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study. Psychooncology. 2017;26(1):74–80. PubMed Voigt V, Neufeld F, Kaste J, Buhner M, Sckopke P, Wuerstlein R, et al. Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study. Psychooncology. 2017;26(1):74–80. PubMed
65.
Zurück zum Zitat Tan CJ, Mah JJJ, Goh WL, Poon E, Harunal Rashid MF, Chan A. Self-reported cognitive outcomes among adolescent and young adult patients with noncentral nervous system cancers. Psychooncology. 2020;29(8):1355–62. PubMedPubMedCentral Tan CJ, Mah JJJ, Goh WL, Poon E, Harunal Rashid MF, Chan A. Self-reported cognitive outcomes among adolescent and young adult patients with noncentral nervous system cancers. Psychooncology. 2020;29(8):1355–62. PubMedPubMedCentral
66.
Zurück zum Zitat Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, et al. Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. J Clin Epidemiol. 2014;67(7):811–20. PubMed Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, et al. Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. J Clin Epidemiol. 2014;67(7):811–20. PubMed
67.
Zurück zum Zitat Dhillon HM, Tannock IF, Pond GR, Renton C, Rourke SB, Vardy JL. Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy. J Cancer Surviv. 2018;12(2):178–85. PubMed Dhillon HM, Tannock IF, Pond GR, Renton C, Rourke SB, Vardy JL. Perceived cognitive impairment in people with colorectal cancer who do and do not receive chemotherapy. J Cancer Surviv. 2018;12(2):178–85. PubMed
68.
Zurück zum Zitat Pullens MJ, De Vries J, Van Warmerdam LJ, Van De Wal MA, Roukema JA. Chemotherapy and cognitive complaints in women with breast cancer. Psychooncology. 2013;22(8):1783–9. PubMed Pullens MJ, De Vries J, Van Warmerdam LJ, Van De Wal MA, Roukema JA. Chemotherapy and cognitive complaints in women with breast cancer. Psychooncology. 2013;22(8):1783–9. PubMed
69.
Zurück zum Zitat Apple AC, Schroeder MP, Ryals AJ, Wagner LI, Cella D, Shih PA, et al. Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy. Neuroimage Clin. 2018;20:110–8. PubMedPubMedCentral Apple AC, Schroeder MP, Ryals AJ, Wagner LI, Cella D, Shih PA, et al. Hippocampal functional connectivity is related to self-reported cognitive concerns in breast cancer patients undergoing adjuvant therapy. Neuroimage Clin. 2018;20:110–8. PubMedPubMedCentral
70.
Zurück zum Zitat Menning S, de Ruiter MB, Veltman DJ, Boogerd W, Oldenburg HS, Reneman L, et al. Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type. PLoS One. 2017;12(3):e171724. PubMedPubMedCentral Menning S, de Ruiter MB, Veltman DJ, Boogerd W, Oldenburg HS, Reneman L, et al. Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type. PLoS One. 2017;12(3):e171724. PubMedPubMedCentral
71.
Zurück zum Zitat Neumann B, Baror R, Zhao C, Segel M, Dietmann S, Rawji KS, et al. Metformin restores CNS remyelination capacity by rejuvenating aged stem cells. Cell Stem Cell. 2019;25(4):473–85.e8. PubMedPubMedCentral Neumann B, Baror R, Zhao C, Segel M, Dietmann S, Rawji KS, et al. Metformin restores CNS remyelination capacity by rejuvenating aged stem cells. Cell Stem Cell. 2019;25(4):473–85.e8. PubMedPubMedCentral
72.
Zurück zum Zitat Wang J, Gallagher D, DeVito LM, Cancino GI, Tsui D, He L, et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell. 2012;11(1):23–35. PubMed Wang J, Gallagher D, DeVito LM, Cancino GI, Tsui D, He L, et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell. 2012;11(1):23–35. PubMed
73.
Zurück zum Zitat Dadwal P, Mahmud N, Sinai L, Azimi A, Fatt M, Wondisford FE, et al. Activating endogenous neural precursor cells using metformin leads to neural repair and functional recovery in a model of childhood brain injury. Stem Cell Reports. 2015;5(2):166–73. PubMedPubMedCentral Dadwal P, Mahmud N, Sinai L, Azimi A, Fatt M, Wondisford FE, et al. Activating endogenous neural precursor cells using metformin leads to neural repair and functional recovery in a model of childhood brain injury. Stem Cell Reports. 2015;5(2):166–73. PubMedPubMedCentral
74.
Zurück zum Zitat Ayoub R, Ruddy RM, Cox E, Oyefiade A, Derkach D, Laughlin S, et al. Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin. Nat Med. 2020;26(8):1285–94. PubMedPubMedCentral Ayoub R, Ruddy RM, Cox E, Oyefiade A, Derkach D, Laughlin S, et al. Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin. Nat Med. 2020;26(8):1285–94. PubMedPubMedCentral
75.
Zurück zum Zitat Karschnia P, Parsons MW, Dietrich J. Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncol. 2019;20(2):e92–e102. PubMed Karschnia P, Parsons MW, Dietrich J. Pharmacologic management of cognitive impairment induced by cancer therapy. Lancet Oncol. 2019;20(2):e92–e102. PubMed
76.
Zurück zum Zitat Harrington CB, Hansen JA, Moskowitz M, Todd BL, Feuerstein M. It’s not over when it’s over: long-term symptoms in cancer survivors—a systematic review. Int J Psychiatry Med. 2010;40(2):163–81. PubMed Harrington CB, Hansen JA, Moskowitz M, Todd BL, Feuerstein M. It’s not over when it’s over: long-term symptoms in cancer survivors—a systematic review. Int J Psychiatry Med. 2010;40(2):163–81. PubMed
77.
Zurück zum Zitat King S, Green HJ. Psychological intervention for improving cognitive function in cancer survivors: a literature review and randomized controlled trial. Front Oncol. 2015;5:72. PubMedPubMedCentral King S, Green HJ. Psychological intervention for improving cognitive function in cancer survivors: a literature review and randomized controlled trial. Front Oncol. 2015;5:72. PubMedPubMedCentral
78.
Zurück zum Zitat Ercoli LM, Petersen L, Hunter AM, Castellon SA, Kwan L, Kahn-Mills BA, et al. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology. 2015;24(11):1360–7. PubMed Ercoli LM, Petersen L, Hunter AM, Castellon SA, Kwan L, Kahn-Mills BA, et al. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psychooncology. 2015;24(11):1360–7. PubMed
79.
Zurück zum Zitat Bray VJ, Dhillon HM, Bell ML, Kabourakis M, Fiero MH, Yip D, et al. Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. J Clin Oncol. 2017;35(2):217–25. PubMed Bray VJ, Dhillon HM, Bell ML, Kabourakis M, Fiero MH, Yip D, et al. Evaluation of a web-based cognitive rehabilitation program in cancer survivors reporting cognitive symptoms after chemotherapy. J Clin Oncol. 2017;35(2):217–25. PubMed
80.
Zurück zum Zitat Hartman SJ, Nelson SH, Myers E, Natarajan L, Sears DD, Palmer BW, et al. Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory & motion study. Cancer. 2018;124(1):192–202. PubMed Hartman SJ, Nelson SH, Myers E, Natarajan L, Sears DD, Palmer BW, et al. Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory & motion study. Cancer. 2018;124(1):192–202. PubMed
81.
Zurück zum Zitat Campbell KL, Zadravec K, Bland KA, Chesley E, Wolf F, Janelsins MC. The effect of exercise on cancer-related cognitive impairment and applications for physical therapy: systematic review of randomized controlled trials. Phys Ther. 2020;100(3):523–42. PubMedPubMedCentral Campbell KL, Zadravec K, Bland KA, Chesley E, Wolf F, Janelsins MC. The effect of exercise on cancer-related cognitive impairment and applications for physical therapy: systematic review of randomized controlled trials. Phys Ther. 2020;100(3):523–42. PubMedPubMedCentral
82.
Zurück zum Zitat Zimmer P, Baumann FT, Oberste M, Wright P, Garthe A, Schenk A, et al. Effects of exercise interventions and physical activity behavior on cancer related cognitive impairments: a systematic review. Biomed Res Int. 2016;2016:1820954. PubMedPubMedCentral Zimmer P, Baumann FT, Oberste M, Wright P, Garthe A, Schenk A, et al. Effects of exercise interventions and physical activity behavior on cancer related cognitive impairments: a systematic review. Biomed Res Int. 2016;2016:1820954. PubMedPubMedCentral
Metadaten
Titel
Cognitive impairment in cancer patients and survivors—clinical presentation, pathophysiology, diagnosis and management
verfasst von
MD Markus Hutterer
Stefan Oberndorfer
Publikationsdatum
05.03.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00690-9